Tetra Bio-Pharma Subsidiary Finishes Phase 3 Topical Trial

Tetra Bio-Pharma’s subsidiary Panag Pharma announced the completion of its Phase 3 clinical trial of a topical, Awaye, treating pain caused by osteoarthritis of the knee.

Tetra Bio-Pharma’s (TSXV:TBP,OTCQB:TBPMF) subsidiary Panag Pharma announced the completion of its Phase 3 clinical trial of a topical, Awaye, treating pain caused by osteoarthritis of the knee.

As quoted in the press release:

The last patient will be finished the open label phase this week and the last follow-up visits will be completed by the end of the third week of June. Panag will complete the analysis of the results and will communicate them to the market in the coming weeks. While the clinical study investigated the use of Awaye for osteoarthritis of the knee, it is currently approved by Health Canada for expanded indications including muscle and joint pain from arthritis.

The Phase 3 trial was a randomized, double-blind, placebo-controlled crossover trial with a 3-week open label

... read more at: https://investingnews.com/daily/cannabis-investing/tetra-bio-pharma-subsidiary-finishes-phase-3-topical-trial/